18 November 2016
A new urine test has shown promise as a means of accelerating the diagnosis of cervical cancer.
Johns Hopkins Medicine researchers have developed a test that analyses not only multiple sources of human cellular DNA altered by precancerous changes, but also the DNA of sexually-transmitted human papillomavirus (HPV) strains that cause virtually all cases of the disease.
In early trials, this test has showed an accuracy rate of 90.9 per cent in identifying CIN2 lesions, which are likely to develop into cancers that pose a greater risk of spreading.
Additionally, they demonstrated that the DNA for all three human genes and one viral gene associated with the disease could be successfully extracted from urine, with such lesions detectable with 75 per cent sensitivity.
Senior investigator Dr Rafael Guerrero-Preston, assistant professor of otolaryngology and head and neck surgery at the Johns Hopkins University School of Medicine, said: "If further studies confirm these findings, we see a significant use of urine screening as a way to quickly and inexpensively determine if a biopsy is warranted, or if physicians can use a watch-and-wait approach before intervening."
Posted by Philip Briggs
Health News is provided by Axonn Media in collaboration with Spire Healthcare. Please note that all copy above is ©Axonn Media and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.